Autologous Stem Cell Transplant In Patients With Hodgkin Lymphoma (HL) and Non-Hodgkin Lymphomas (NHL)
Masonic Cancer Center, University of Minnesota
Summary
This is a phase II study of autologous transplant for patients with Hodgkin (HL) and non-Hodgkin lymphomas (NHL) including those who are HIV positive.
Eligibility
- Age range
- Up to 75 years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Eligible Diseases 1. Non-Hodgkin's Lymphoma (NHL) * Patients with chemo-sensitive histologically confirmed NHL will be eligible for this treatment protocol contingent on histologic sub-classification. * Patients in partial or complete remission following cell therapy will also be eligible. * NHL patients with resistant or refractory lymphoma (no PR following up to three cycles of combination chemotherapy) will not be eligible for transplant in this trial. * Lymphoblastic Lymphoma: 1. All patients will be eligible in second or greater compl…
Interventions
- DrugEtoposide
BEAM: 100 mg/m\^2 IV over 2 hours BID on Days -5, -4, -3, -2 \| CBV: 150 mg/m\^2 intravenously over 4 hours every 12 hours starting at 6 a.m. and 6 p.m. on Days -6, -5, -4
- DrugBCNU
BEAM \& CBV: 300 mg/m\^2 IV over over 2 hours on Day -6
- DrugAraC
BEAM: 100 mg/m\^2 IV over 1 hour BID on Days -5, -4, -3, -2
- DrugMelphalan
BEAM: 140 mg/m\^2 IV over 20 minutes on Day -1
- ProcedurePeripheral blood stem cell transplantation
All Arms: Day 0 infuse PBSC. All patients will have PBSC collected by leukapheresis. Mobilization will be done with G-CSF.
- BiologicalG-CSF
All patients should receive G-CSF, 5 ug/kg/day IV as a bolus injection each evening beginning on day +5 until the ANC is \>2500 x 10\^9/L for 2 consecutive days. G-CSF will subsequently be restarted at 5 ug/kg/day SC or IV if the ANC falls below 1000/mm\^3
Location
- Masonic Cancer Center, University of MinnesotaMinneapolis, Minnesota